Vaccine adjuvant therapy for colorectal cancer: "very dramatic" or ho- hum?
CG Moertel
JCO Mar 1 1993: 385–386. [PDF]
MVAC for bladder cancer: time to move forward again
EG Levine and D Raghavan
JCO Mar 1 1993: 387–389. [PDF]
	Adjuvant active specific immunotherapy for human colorectal cancer: 6.5- year median follow-up of a phase III prospectively randomized trial
	HC Hoover, Jr, JS Brandhorst, LC Peters, MG Surdyke, Y Takeshita, J Madariaga, LR Muenz, and MG Hanna, Jr
	JCO Mar 1 1993: 390–399. [Abstract] [PDF]
	Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC
	HI Scher, NL Geller, T Curley, and Y Tao
	JCO Mar 1 1993: 400–407. [Abstract] [PDF]
	Dose-intensification of MVAC with recombinant granulocyte colony- stimulating factor as initial therapy in advanced urothelial cancer
	AD Seidman, HI Scher, JL Gabrilove, DF Bajorin, RJ Motzer, M O'Dell, T Curley, DD Dershaw, S Quinlivan, and Y Tao
	JCO Mar 1 1993: 408–414. [Abstract] [PDF]
	Second cancer risk following testicular cancer: a follow-up study of 1,909 patients
	FE van Leeuwen, AM Stiggelbout, AW van den Belt-Dusebout, R Noyon, MR Eliel, EH van Kerkhoff, JF Delemarre, and R Somers
	JCO Mar 1 1993: 415–424. [Abstract] [PDF]
	Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer
	OT Atiq, DP Kelsen, MH Shiu, L Saltz, W Tong, D Niedzwiecki, B Trochanowski, S Lin, F Toomasi, and M Brennan
	JCO Mar 1 1993: 425–433. [Abstract] [PDF]
	Secondary cytoreduction for ovarian cancer following cisplatin therapy
	RA Segna, PR Dottino, JP Mandeli, K Konsker, and CJ Cohen
	JCO Mar 1 1993: 434–439. [Abstract] [PDF]
	A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: a North Thames Ovary Group study
	HE Lambert, GJ Rustin, WM Gregory, and AE Nelstrop
	JCO Mar 1 1993: 440–448. [Abstract] [PDF]
	Osteogenic sarcoma with clinically detectable metastasis at initial presentation
	PA Meyers, G Heller, JH Healey, A Huvos, A Applewhite, M Sun, and M LaQuaglia
	JCO Mar 1 1993: 449–453. [Abstract] [PDF]
	Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer
	M Kaufmann, W Jonat, U Abel, J Hilfrich, H Caffier, R Kreienberg, G Trams, K Brunnert, J Schermann, and W Kleine
	JCO Mar 1 1993: 454–460. [Abstract] [PDF]
	Ifosfamide and mitoxantrone as first-line chemotherapy for metastatic breast cancer
	JE Perez, M Machiavelli, BA Leone, A Romero, MG Rabinovich, CT Vallejo, A Bianco, JA Lacava, R Rodriguez, and MA Cuevas
	JCO Mar 1 1993: 461–466. [Abstract] [PDF]
	Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration
	C Blomqvist, I Elomaa, P Rissanen, P Hietanen, K Nevasaari, and L Helle
	JCO Mar 1 1993: 467–473. [Abstract] [PDF]
	Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer
	MA Cobleigh, K Dowlatshahi, TA Deutsch, RG Mehta, RC Moon, F Minn, AB Benson, 3d, AW Rademaker, JB Ashenhurst, and JL Wade, 3d
	JCO Mar 1 1993: 474–477. [Abstract] [PDF]
	Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer
	MJ Kennedy, GB Vogelsang, RA Beveridge, ER Farmer, V Altomonte, AM Huelskamp, and NE Davidson
	JCO Mar 1 1993: 478–484. [Abstract] [PDF]
	High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients
	U Magriples, F Naftolin, PE Schwartz, and ML Carcangiu
	JCO Mar 1 1993: 485–490. [Abstract] [PDF]
	Palliative pamidronate treatment in patients with bone metastases from breast cancer
	AT van Holten-Verzantvoort, HM Kroon, OL Bijvoet, FJ Cleton, LV Beex, G Blijham, J Hermans, JP Neijt, SE Papapoulos, and HP Sleeboom
	JCO Mar 1 1993: 491–498. [Abstract] [PDF]
	Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies
	J Weber, JC Yang, SL Topalian, DR Parkinson, DS Schwartzentruber, SE Ettinghausen, H Gunn, A Mixon, H Kim, and D Cole
	JCO Mar 1 1993: 499–506. [Abstract] [PDF]
	Pregnancy outcome in patients treated for Hodgkin's disease
	J Aisner, PH Wiernik, and P Pearl
	JCO Mar 1 1993: 507–512. [Abstract] [PDF]
	Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation
	BM Bar, A Schattenberg, EJ Mensink, A Geurts Van Kessel, TF Smetsers, GH Knops, EH Linders, and T De Witte
	JCO Mar 1 1993: 513–519. [Abstract] [PDF]
	Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report
	DG Tubergen, GS Gilchrist, RT O'Brien, PF Coccia, HN Sather, MJ Waskerwitz, and GD Hammond
	JCO Mar 1 1993: 520–526. [Abstract] [PDF]
	Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial
	DG Tubergen, GS Gilchrist, RT O'Brien, PF Coccia, HN Sather, MJ Waskerwitz, and GD Hammond
	JCO Mar 1 1993: 527–537. [Abstract] [PDF]
	Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Childrens Cancer Group
	RJ Wells, WG Woods, BC Lampkin, ME Nesbit, JW Lee, JD Buckley, C Versteeg, and GD Hammond
	JCO Mar 1 1993: 538–545. [Abstract] [PDF]
	Molecular residual disease status at the end of chemotherapy fails to predict subsequent relapse in children with B-lineage acute lymphoblastic leukemia
	Y Ito, R Wasserman, N Galili, BA Reichard, S Shane, B Lange, and G Rovera
	JCO Mar 1 1993: 546–553. [Abstract] [PDF]
	Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors
	NM Marina, J Rodman, SJ Shema, LC Bowman, E Douglass, W Furman, VM Santana, M Hudson, J Wilimas, and W Meyer
	JCO Mar 1 1993: 554–560. [Abstract] [PDF]
	Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group
	SA Grossman, DM Finkelstein, JC Ruckdeschel, DL Trump, T Moynihan, and DS Ettinger
	JCO Mar 1 1993: 561–569. [Abstract] [PDF]
	The Functional Assessment of Cancer Therapy scale: development and validation of the general measure
	DF Cella, DS Tulsky, G Gray, B Sarafian, E Linn, A Bonomi, M Silberman, SB Yellen, P Winicour, and J Brannon
	JCO Mar 1 1993: 570–579. [Abstract] [PDF]
Adjuvant therapy for breast cancer: understanding the overview. International Breast Cancer Study Group
RD Gelber, A Goldhirsch, and AS Coates
JCO Mar 1 1993: 580–585. [PDF]
Acute nonlymphocytic leukemia after small-cell lung cancer
LB Travis, RE Curtis, BF Hankey, and JF Fraumeni, Jr
JCO Mar 1 1993: 586a–587. [PDF]
Dr Hoover responds to Dr Moertel
HC Hoover, Jr
JCO Mar 1 1993: 586b. [PDF]
Dodging the dogma
E Brand and SA Davidson
JCO Mar 1 1993: 587–588. [PDF]
Retinoids as anticancer agents
FL Meyskens, Jr
JCO Mar 1 1993: 588–589. [PDF]
All-trans-retinoic acid in acute promyelocytic leukemia: let's get on with finding out how good it is
RE Gallagher
JCO Mar 1 1993: 589–590. [PDF]
Secondary acute myeloid leukemia after autologous bone marrow transplantation for malignant lymphomas
JP Marolleau, P Brice, P Morel, and C Gisselbrecht
JCO Mar 1 1993: 590–591. [PDF]

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.